Advances in potential therapeutic uses of inhibitors of CNS selective amino acid transporters

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 4, 2001, Pages 563-572

  Armer, R E ^a   Miller, D J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arginine; CNS application; GABA; Glutamate; Glycine; Neurodegeneration; Proline; Psychiatry; Taurine; Transport inhibitor; Uptake inhibitor

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)NIPECOTIC ACID; 1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 1 [2 [4,4' BIS(TRIFLUOROMETHYL)BENZHYDRYLOXY]ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 3 HYDROXYASPARTIC ACID; 4 AMINOBUTYRIC ACID; ALX 1393; ALX 1405; ALX 5407; AMINO ACID; ANTITUSSIVE AGENT; BETA CARBOLINE DERIVATIVE; CARBAZOLE DERIVATIVE; CARRIER PROTEIN; CLOZAPINE; CYSTEINE DERIVATIVE; DIBENZAZEPINE DERIVATIVE; ETHER DERIVATIVE; GLUTAMIC ACID; GLYCINE; GUVACINE; HALOPERIDOL; LYCOPODIUM CRASSUM EXTRACT; NATURAL PRODUCT; NIPECOTIC ACID DERIVATIVE; OXIME DERIVATIVE; PROLINE; SARCOSINE; SERINE DERIVATIVE; TIAGABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; COUGHING; DEGENERATIVE DISEASE; DEPRESSION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ELEPHANTIASIS; EPILEPSY; GUINEA PIG; HUMAN; ISCHEMIA; LYCOPODIUM CRASSUM; MEDICAL RESEARCH; MICTURITION DISORDER; MODULATION; NEUROMODULATION; NONHUMAN; PAIN; PATENT; PLANT; PSYCHOSIS; RAT; REVIEW; RODENT; SCHIZOPHRENIA; SEIZURE; SYNAPSE;

EID: 0035070870     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.4.563     Document Type: Review

References (38)

1. Molecular biology of mammalian plasma membrane amino acid transporters
2. Molecular characteristics of mammalian and insect amino acid transporters: Implications for amino acid homeostasis
3. 1-(3-(9H-Carbazol-9-y1)-1-propoyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse Type II GABA-transporter
4. Inhibitors of mammalian central nervous system selective amino acid transporters
5. The GABA transporter and its inhibitors
6. Tiagabine
7. Orally active and potent inhibitors of GABA uptake
8. NNC-711, a novel potent and selective GABA uptake inhibitor: Pharmacological characterization
9. Synthesis of novel GABA uptake inhibitors. 3. Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine as anticonvulsant agents
10. Synthesis of novel GABA uptake inhibitors. 4. Bioisosteric transformation and successive optimization of known GABA uptake inhibitors leading to a series of potent anticonvulsant drug candidates
11. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1
12. Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally-active inhibitors of GABA uptake
13. Pharmacology of CI-966: A potent GABA uptake inhibitor, in vitro and in experimental animals
14. GABA receptors and GABAergic synapses as targets for drug development
15. Characterization of the 5′ region of the rat brain glycine transporter GLYT2 gene: Identification of a novel isoform
16. Atypical antipsychotics
17. Developments in antipsychotic drugs an update
18. Novel glycine transporter 2 inhibitors are analgesic in a rat model of inflammatory pain
19. Modulation of NMDA receptor function by glycine transport
20. High affinity glutamate transporters: Regulation of expression and activity
21. Excitatory amino acid transporters as emerging targets for central nervous system therapeutics
22. The role of glutamate neurotoxicity in hypoxy-ischaemic neuronal death
23. Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms
24. Ligands for glutamate receptors: Design and therapeutic prospects
25. Recent advances in novel atypical antipsychotic agents: Potential therapeutic agents for the use in the treatment of schizophrenia
26. Glutamatergic aspects of schizophrenia
27. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum
28. Glutamate transporter alterations in Alzheimer's disease are possibly associated with abnormal APP expression
29. Interindividual differences in the levels of glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease
30. New β-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter
31. DL-Threo-β-hydroxyaspartate, a potent blocker of excitatory amino acid transporters
32. Conformationally restricted inhibitors of the high affinity L-glutamate transporter
33. A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain
34. Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain
35. Pharmacology of the inhibitory glycine receptor: Agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds
36. Carnosine and taurine protect rat cerebella granular cells from free radical damage
37. 2+ sequestration by taurine
38. Molecular characterisation and in situ localisation of a mouse retinal taurine transporter